Clinical Trials

Phase 1 Not yet recruiting

40 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT07363369 2026-01-23

Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

10 enrolled

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

40 enrolled

Other solid neoplasm

Advanced Refractory Solid Tumors

NCT07317778 2026-01-05

Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

249 enrolled

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

NCT07271602 2025-12-09

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

Phase 3 Not yet recruiting

104 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07238569 2025-11-20

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

516 enrolled

Head & Neck

Nasopharyngeal Cancinoma (NPC)

NCT07230301 2025-11-17

Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions

20 enrolled

Phase 1/2 Not yet recruiting

Pancreatic Cancer Metastatic

NCT05806385 2025-09-09

LOGIC

36 enrolled

Triple Negative Breast Neoplasms

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT07157306 2025-09-05

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

35 enrolled

Phase 4 Not yet recruiting

Carcinoma, Hepatocellular

NCT07149181 2025-08-29

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery

1,000 enrolled

Phase 4 Not yet recruiting

Gastric / Gastroesophageal Junction Adenocarcinoma

NCT07132528 2025-08-20

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

1,000 enrolled

Phase NA Not yet recruiting

Gastric / Gastroesophageal Junction Adenocarcinoma

NCT07101536 2025-08-03

The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV)

40 enrolled

EBV-associated Tumors

NCT07064668 2025-07-15

Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study

300 enrolled

Phase 1 Not yet recruiting

Carcinoma, Hepatocellular

NCT06966583 2025-05-12

NMN

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06957977 2025-05-06

A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer

42 enrolled

Phase 4 Not yet recruiting

Stomach Neoplasms

NCT06951841 2025-04-30

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06890624 2025-03-27

OPTICAL-3

138 enrolled

Colonic Neoplasms

NCT06889402 2025-03-21

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

600 enrolled

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

NCT06835179 2025-02-19

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

28 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT06733233 2024-12-13

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

23 enrolled

Phase NA Not yet recruiting

Breast Neoplasms

NCT06708650 2024-11-27

Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma

50 enrolled

Carcinoma, Hepatocellular

NCT06646666 2024-11-01

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

35 enrolled

Lymphoid

Lymphoma, B-Cell

NCT06522542 2024-07-26

Gastric Cancer Complicated With Bleeding

200 enrolled

Stomach Neoplasms

NCT06464601 2024-06-18

A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer

70 enrolled

Stomach Neoplasms

NCT06448169 2024-06-07

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

200 enrolled

Hypersensitivity, Triple Negative Breast Neoplasms

NCT06304987 2024-03-19

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

50 enrolled